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Abstract - Elevated serum ferritin .levels have been observed in several disease states 
including various malignancies, inflammatory states, and the acquired immunodeficiency 
syndrome (AIDS). This discussion will examine the normal sequence of events in T cell 
activation and proliferation, as well as the various defects in these events, and 
monocyte/macrophage and NK cell activity seen in AIDS patients. Further, the potential 
role of a serum suppressor factor as a contributor to the profound immunosuppression 
seen in AIDS will be discussed, as will evidence suggesting that ferritin may be this factor. 
A model is presented to explain mechanisms by which ferritin might suppress immune 
function and further studies to elaborate these mechanisms are proposed. 
Introduction 
Elevated serum ferritin levels have been noted 
in patients with various malignancies including 
Hodgkin’s disease (1, 2), breast cancer (3, 4) and 
neuroblastoma (5), and more recently in patients 
with AIDS and AIDS-related complex (ARC) 
(6). This discussion will focus on the graded 
elevation of ferritin levels seen in patients with 
ARC and AIDS (6), and propose a model for 
the role of ferritin in the pathogenesis of AIDS. 
The etiologic agent responsible for the 
acquired immune deficiency syndrome (AIDS) 
is the human T lymphotropic virus type III 
(HTLV-III) (7, S), now known as the human 
immunodeficiency virus (HIV). HIV binds to 
cells bearing the CD4 (T4) antigen on the cell 
surface, and in so doing is able to infect helper 
T lymphocytes (9, lo), monocyte/macrophages 
(11, 12), epidermal Langerhans cells (13), and 
neurons and g1ia.l cells in the CNS (9, 14). 
T-cell activation 
Patients with AIDS have a variety of defects in 
immune function, which for the most part may 
be explained by depletion and/or functional 
disruption of helper/inducer T lymphocytes. Of 
particular concern here are the defects in T 
lymphocyte, as well as natural killer (NK) and 
monocyte/macrophage function. Before 
considering the various defects, the normal 
sequence of events in T cell activation will be 
discussed. Activation of T lymphocytes requires 
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interaction of ligand with cell surface receptors 
and generation of intracellular signals, which in 
turn lead to the expression of activation markers 
(i.e. receptors for interleukin-2 and transferrin) 
(15-18), interleukin-2 (IL-2) production (19), 
and ultimately T cell proliferation Synthesis and 
expression of the interleukin-2 receptor (IL-2R) 
is an early event (20), while IL-2 production 
peaks within 24 hours of antigen stimulation (15) 
and transferrin receptor (Tf-R) expression peaks 
after 48 hours post-exposure (20). IL-2 regulates 
the expression of its own receptors as well as 
those for transferrin (Tf) (18, 21-23). IL-2 and 
transferrin receptor expression appears to be 
required for DNA synthesis and proliferation by 
activated T cells (18), as is the interaction of IL- 
2 (19, 24) and transferrin (18, 25) with these 
receptors. Monoclonal antibodies against the Tf- 
R inhibit cell growth in vitro (26-29), and inhibit 
the generation of cytotoxic T lymphocytes (30). 
Cytotoxic T lymphocytes produce interferon-y 
(IFN-y) in response to antigens or mitogens (38, 
39), under the positive influence of IL-2 (33, 35). 
IL-2 is produced by helper T lymphocytes (40, 
42). 
T cell defects 
AIDS patients have several qualitative defects in 
the activation and proliferation of T lympho- 
cytes, in addition to the well documented 
lymphopenia and inversion of the 
helper/suppressor T lymphocyte ratio (36-43). 
These defects include decreased IL-2 production 
(36, 39, 44) and IL-2R expression (36, 38, 44), 
as well as decreased IFNy production (37, 45, 
46) and cytotoxic T cell activity (47). More 
general measures of T lymphocyte function show 
decreased in vitro proliferation in response to 
mitogens (36-39, 41-43, 48), antigens (41, 43, 
48), or alloantigens (40, 43), as well as decreased 
E-rosette formation (42, 43, 48) and skin test 
reactivity (43, 48). Exogenous IL-2 can partially 
restore mitogen-induced lymphocyte prolifera- 
tion (39) and cytotoxic T cell activity (47) in 
vitro. In vivo, infusions of IL-2 cause a poly- 
clonal expansion of T cells and IL-2R expression, 
but apparently have no impact on transferrin 
receptor expression or subsequent mitogen- 
induced T cell proliferation in vitro (49). IL-2 
enhances IFN-y production by normal lympho- 
cytes, but not those from AIDS patients (46). It 
appears then. that in addition to being decreased 
in total number, T lymphocytes from AIDS 
patients have functional defects in both early and 
late stages of maturation. In that in vivo admin- 
istration of IL-2 has no effect on transferrin 
receptor expression or T cell proliferation, and 
only partially restores T cell proliferation when 
added in vitro, it would appear that there may 
be an extrinsic factor in vivo which suppresses 
late stages of T cell activation. Further, although 
early stages of activation such as IL-2 production 
and IL-2R expression may be limited by an 
intrinsic defect of the infected T cell, it is poss- 
ible that an extrinsic factor abrogates these as 
well. 
Monocyte/macrophage and NK cell defects 
The defects in T ceil activation and elaboration 
of lymphokines (IL-2 and IFN-y), and the 
resultant reduction in T cell proliferation may 
secondarily limit dependent effector mecha- 
nisms, including monocyte/macrophage and 
natural kill cell activity. In normal individuals, 
IFN-y activates macroph?ges to kill microbial or 
tumor targets (50, 51). AIDS patients are seen 
to have diminished monocyte chemotaxis (52), 
and monocyte/macrophage killing of tumor 
targets (53, 54). Exogenous IFN-y can restore 
killing of both tumor (53) and microbial (37) 
targets by monocyte/macrophages from these 
patients. IFN-y augments the expression of class 
II major histocompatability complex (MHC) 
antigens on normal monocyte/macrophages (55). 
Not surprisingly, class II MHC expression is 
decreased on the monocyte/macrophage from 
AIDS patients, and can be restored to near 
normal levels by IFN-y treatment in vitro (56). 
Interaction of helper T cells with antigen- 
presenting cells (APC), such as the 
monocyte/macrophage, is an MHC-II restricted 
process. Defects in helper T cell function then, 
may also reflect primary defects in the APC. 
AIDS patients have decreased natural killer 
(NK) activity (43, 47). IL-2 (46, 57,58) and IFN- 
y (46, 59) enhance NK activity in both normal 
and AIDS patients, and do so via independent 
mechanisms (60). It is worth noting that NK 
activity appears to be important in the destruc- 
tion of HIV-infected target cells (61), and 
interferon-y suppresses the replication of HIV in 
vitro (62). Given the deficits in T cell activation 
and IL-2/IFN-y production, the observed corre- 
lation between decreased interferon-y production 
and the progression of disease from ARC to 
AIDS (45), and the deficits in IL-2/IFN-y 
dependent effector functions, the question then 
remains, what is it that disrupts effective T cell 
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activation, lymphokine production and 
proliferation? 
A soluble suppressor 
Several studies have demonstrated circulating 
factor(s) in the serum of AIDS patients which 
can suppress T cell activation and proliferation 
(63-67). This factor(s) suppresses mitogen- 
induced IL-2 production and IL-2R expression 
(63, 65) by normal lymphocytes, proliferation of 
IL-2 dependent cytotoxic T cell lines in response 
to IL-2 (63, 64), and proliferation of normal 
lymphocytes in response to mitogens, soluble 
antigens, or alloantigens in the mixed lympho- 
cyte reaction (MLR) (65, 67). The factor has the 
following characteristics (66): not lymphotoxic, 
stable @ pH 3-10 and up to, 6O”C, inactivated 
@ lOO”C, not ether extractable, not interferon, 
cortisol, IgG, IgM or an immune complex, not 
mediated by radiosensitive or T8 antigen-bearing 
suppressor cells, or increased prostaglandin E or 
decreased IL-1 production, does not reflect 
absence of a stimulatory or nutritive factor, 
inactivation of IL-2, inhibition of the IL-2 assay, 
or increased IL-2 turnover. 
The suppressive effects of AIDS sera on 
normal lymphocytes persists after the cells have 
been washed, suggesting that the factor may be 
able to bind to receptors on lymphocytes (66). 
Pretreatment of IL-2R+ lymphoblasts with 
AIDS serum does not block binding of anti-IL- 
2R monoclonal antibodies (63), so the suppressor 
apparently does not act by blocking the IL-2 
receptor. Further, gel filtration of serum from 
AIDS patients shows that the inhibitory activity 
coelutes with the immunoglobulin fraction (63). 
Immunoglobulins have molecular weights ranging 
from 150 000 daltons for IgG to 950 000 daltons 
for IgM. Ferritin has a molecular weight of 
approximately 460 000 dalton, and thus would be 
expected to coelute with the immunoglobulin 
fraction. It is proposed here that ferritin may be 
the circulating inhibitor. 
Ferritin as the suppressor? 
Several observations suggest that ferritin, 
particularly at the levels seen in AIDS patients, 
may be capable of suppressing T lymphocyte 
function. Ferritin suppresses mitogen-induced T 
lymphocyte blastogenesis (68-70). Although not 
examined specifically in T lymphocytes, ferritin 
and transferrin appear to utilize a common 
receptor-mediated endocytosis pathway in reti- 
culocytes (71). and ferritin can disrupt transferrin 
endocytosis and reduce intracellular iron 
accumulation (72). As noted above, expression 
of the transferrin receptor (18) and interaction 
of transferrin with this receptor (18, 25) are 
required events in the activation and prolifera- 
tion of T cells. In fact, monoclonal antibodies 
directed against the transferrin receptor have 
been shown to inhibit mitogen-induced prolifer- 
ation (73), the MLR (30), and the generation of 
cytotoxic T cells (30). 
By abrogating the receptor-mediated endocy- 
tosis of transferrin by T lymphocytes, ferritin 
may disrupt late stages of T cell activation, and 
by limiting T cell proliferation, the overall 
production of IL-2 and IFN-y may be reduced. 
Conclusion 
As noted above, one study has demonstrated 
elevated serum ferritin levels in a small sample 
of AIDS and ARC patients (6). Several consid- 
erations, however, should be noted regarding 
this study. Ferritin may be nonspecifically elev- 
ated in inflammatory conditions (74). and 
various malignancies (l-4). The above study, 
however, uses only healthy heterosexuals as 
controls. More meaningful conclusions might be 
drawn if ferritin levels were also compared to 
those from patients with other conditions where 
ferritin is known to be elevated. Further, a mean 
serum ferritin for healthy heterosexual controls 
is reported as 160 pg/dl (i.e., 16 000 ng/ml), 
while most acknowledge the “normal” range to 
be O-250 ng/ml (75). Given the extremely high 
values reported for normal controls, and the 
need for additional controls for comparison, it 
would be useful to more extensively explore the 
significance of elevated serum ferritin levels in 
AIDS patients. Preliminary examination here in 
6 patients with CDC-defined AIDS has revealed 
a mean serum ferritin of 5 028 rig/ml (R 
2,072-12,174 ng’ml). 
No substantial proposal has been made 
regarding the significance of elevated ferritin 
levels in the pathogenesis of AIDS. It is 
proposed here that ferritin may disrupt func- 
tional processing of the transferrin (Tf) Tf- 
receptor complex and in so doing, limit T cell 
activation and proliferation. By limiting T cell 
proliferation, ferritin may indirectly cause reduc- 
tion in the total lymphokine output of a given 
population of lymphocytes, and abrogate 
lymphokine-dependent immune function. Ferritin 
might directly limit IL-2 and IFN-y production 
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as well. It would be useful to directly examine 
the impact of ferritin, at concentrations such as 
those seen in AIDS patients, on the processing 17. 
of transferrin and production of IL-2 and IFN- 
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